Toll-IL1 receptor-mediated innate immune responses vary across HBV genotype and predict treatment response to pegylated-IFN in HBeAg-positive CHB patients
K Visvanathan, T Lang, K Ryan, R Wilson, NA Skinner, AJV Thompson, SH Ahn, F Weilert, W Abbott, E Gane, D Colledge, K Li, S Locarnini, A Mansell, PA Revill
Journal of Viral Hepatitis | WILEY | Published : 2016
Patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) have suppressed TLR2 expression, function and cytokine production. The aim of this study was to explore the importance of hepatitis B virus (HBV) genotype in innate immune responses and investigate whether Toll-like receptor (TLR) expression/function has potential roles as predictive biomarkers of successful therapy with pegylated interferon (Peg-IFN) therapy of HBeAg seroconversion in HBeAg-positive patients. We showed that as early as 4 weeks after initiation of Peg-IFN, future HBeAg seroconverters had significantly elevated levels of TLR2 expression on monocytes. TLR2-associated IL-6 production at baseline and ..View full abstract
Awarded by NHMRC
This work was funded in part by NHMRC project grant 491017.